Reagents will lead diagnostic exosome biomarkers sales through 2036 with a 46.2% share in 2026 as the leading product type segment. The market was valued at USD 266.10 million in 2025 and is expected to reach USD 1348.85 million by 2036, creating an incremental opportunity of USD 1040.44 million.